Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: a prespecified secondary analysis of a randomised clinical trial
Quick summary for GPs Wegovy (semaglutide) is a once-weekly GLP-1 receptor agonist approved in New Zealand for chronic weight management
Apply multiple layers of light and moisturizing serum texture to make brighter skin
PlexusDx offers compounded GLP-1 formulations (from licensed 503A pharmacies) and genetic testing to support this precision approach, allowing your care team to make decisions tailored to your unique biology and disease state
GLP-1 Therapy Shifts from Molecule to Delivery The GLP-1 Race Is No Longer About the Molecule Its About Delivery On January 12, 2026, Chinas CDE approved Shiling Pharmas Semaglutide Nasal Spray for clinical trials in long-term weight managementmarking the worlds first mucosal GLP-1 therapy (Class 2.2 innovation)
The inhibition of mTOR results in the suppression of anti-apoptotic proteins, promoting cell death